Avid Bioservices' stock plummeted 30% post-earnings; Q3 revenue fell 11%, with significant drops in gross margin and operating income. Announced planned $160 million 7.00% Convertible Senior Notes; ...

--Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization working to improve patient lives by providing high quality development and manufacturing services to ...

Avid reported quarterly fiscal results on Tuesday. The company reported sales of $43 million beating analyst estimates of $42.14 million. Every week, our Whisper Index uncovers five overlooked stocks ...

-- Signed $35 Million in Net New Business Orders Resulting in a Backlog of $199 Million-- “Despite the challenges of the first half of fiscal 2024, our current backlog and pipeline position us well to ...

Avid Bioservices, Inc. (CDMO) Investigation: Avid shares fell on Mar. 12, 2024 after the CDMO announced the need to restate its financial performance over several quarters in 2022 and 2023. The ...

-- New Mammalian and Cell and Gene Therapy Facilities Fully Operational and in Service; Capital Expenditure Associated with Three-Year Expansion Program Completed -- -- FY 2025 Revenue Guidance of ...

TUSTIN, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient ...

-- Recorded First Quarter Revenue of $40.2 Million -- -- Signed $66 Million in Net New Business, Resulting in Backlog of $219 Million -- -- Maintained FY2025 Revenue Guidance of Between $160 Million ...

TUSTIN, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient ...